Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James A Dowell

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Journal of Clinical Pharmacology|October 22, 2005
Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptideMary Buckwalter, James A Dowell
Plos One|August 8, 2013
Mechanisms of Nrf2 protection in astrocytes as identified by quantitative proteomics and siRNA screeningJames A Dowell, Jeffrey A Johnson
Antimicrobial Agents and Chemotherapy|August 9, 2021
Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase InhibitorJames A Dowell, Daniel Dickerson, Tim Henkel
Methods in Molecular Biology (Clifton, N.J.)|February 26, 2009
Mass spectrometric characterization of neuropeptidesStephanie S Cape, James A Dowell, Lingjun Li
Methods in Molecular Biology (Clifton, N.J.)|December 17, 2009
Rat brain neuropeptidomics: tissue collection, protease inhibition, neuropeptide extraction, and mass spectrometric analysisRobert M Sturm, James A Dowell, Lingjun Li
Journal of Proteome Research|December 2, 2006
Rat neuropeptidomics by LC-MS/MS and MALDI-FTMS: Enhanced dissection and extraction techniques coupled with 2D RP-RP HPLCJames A Dowell, William Vander Heyden, Lingjun Li
Journal of Proteome Research|May 28, 2009
Identification of astrocyte secreted proteins with a combination of shotgun proteomics and bioinformaticsJames A Dowell, Jeffrey A Johnson, Lingjun Li
Journal of Clinical Pharmacology|March 26, 2009
Pharmacokinetics of dalbavancin in patients with renal or hepatic impairmentThomas Marbury, James A Dowell, Elyse Seltzer, et al.
Journal of Clinical Pharmacology|May 21, 2008
Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney diseaseWilliam Knebel, Mary Palmen, James A Dowell, et al.
Journal of Clinical Pharmacology|March 29, 2007
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairmentJames A Dowell, Martin Stogniew, David Krause, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pharmacology|October 22, 2005
Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptideMary Buckwalter, James A Dowell
Plos One|August 8, 2013
Mechanisms of Nrf2 protection in astrocytes as identified by quantitative proteomics and siRNA screeningJames A Dowell, Jeffrey A Johnson
Antimicrobial Agents and Chemotherapy|August 9, 2021
Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase InhibitorJames A Dowell, Daniel Dickerson, Tim Henkel
Methods in Molecular Biology (Clifton, N.J.)|February 26, 2009
Mass spectrometric characterization of neuropeptidesStephanie S Cape, James A Dowell, Lingjun Li
Methods in Molecular Biology (Clifton, N.J.)|December 17, 2009
Rat brain neuropeptidomics: tissue collection, protease inhibition, neuropeptide extraction, and mass spectrometric analysisRobert M Sturm, James A Dowell, Lingjun Li
Journal of Proteome Research|December 2, 2006
Rat neuropeptidomics by LC-MS/MS and MALDI-FTMS: Enhanced dissection and extraction techniques coupled with 2D RP-RP HPLCJames A Dowell, William Vander Heyden, Lingjun Li
Journal of Proteome Research|May 28, 2009
Identification of astrocyte secreted proteins with a combination of shotgun proteomics and bioinformaticsJames A Dowell, Jeffrey A Johnson, Lingjun Li
Journal of Clinical Pharmacology|March 26, 2009
Pharmacokinetics of dalbavancin in patients with renal or hepatic impairmentThomas Marbury, James A Dowell, Elyse Seltzer, et al.
Journal of Clinical Pharmacology|May 21, 2008
Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney diseaseWilliam Knebel, Mary Palmen, James A Dowell, et al.
Journal of Clinical Pharmacology|March 29, 2007
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairmentJames A Dowell, Martin Stogniew, David Krause, et al.
Pageof 4